W
Wenqing Yao
Researcher at Incyte
Publications - 200
Citations - 3904
Wenqing Yao is an academic researcher from Incyte. The author has contributed to research in topics: Cancer & Kinase. The author has an hindex of 29, co-authored 188 publications receiving 3576 citations. Previous affiliations of Wenqing Yao include Bristol-Myers Squibb & Wilmington University.
Papers
More filters
Journal ArticleDOI
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
Bin-Bing S. Zhou,Michael Peyton,Biao He,Changnian Liu,Luc Girard,Eian Caudler,Yvonne Lo,Frédéric Baribaud,Iwao Mikami,Noemi Reguart,Gengjie Yang,Yanlong Li,Wenqing Yao,Kris Vaddi,Adi F. Gazdar,Steven Friedman,David M. Jablons,Robert C. Newton,Jordan S. Fridman,John D. Minna,Peggy Scherle +20 more
TL;DR: The results show that ADAM inhibition affects multiple ErbB pathways in NSCLC and thus offers an excellent opportunity for pharmacological intervention, either alone or in combination with other drugs.
Journal ArticleDOI
Aggrecan protects cartilage collagen from proteolytic cleavage.
Michael A. Pratta,Wenqing Yao,Carl P. Decicco,Micky D. Tortorella,Riu-Qin Liu,Robert A. Copeland,Ronald L. Magolda,Robert C. Newton,James M. Trzaskos,Elizabeth C. Arner +9 more
TL;DR: It is suggested that aggrecan plays a protective role in preventing degradation of collagen fibrils, and that an aggre canase inhibitor may impart overall cartilage protection.
Journal ArticleDOI
A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu,Qian Wang,Gengjie Yang,Cindy Marando,Holly Koblish,Leslie Hall,Jordan S. Fridman,Elham Behshad,Richard Wynn,Yu Li,Jason Boer,Sharon Diamond,Chunhong He,Meizhong Xu,Jincong Zhuo,Wenqing Yao,Robert Newton,Peggy A. Scherle +17 more
TL;DR: Activated c-MET has pleiotropic effects on multiple cancer-promoting signaling pathways and may play a critical role in driving tumor cell growth and survival and may have therapeutic potential in cancer treatment.
Journal ArticleDOI
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Phillip Liu,Xiangdong Liu,Yanlong Li,Maryanne B. Covington,Richard Wynn,Reid Huber,M.C. Hillman,Gengjie Yang,Dawn Ellis,Cindy Marando,Kamna Katiyar,Jodi D. Bradley,Kenneth Abremski,Mark Stow,Mark Rupar,Jincong Zhuo,Yun-Long Li,Qiyan Lin,David M. Burns,Meizhong Xu,Colin Zhang,Ding-Quan Qian,Chunhong He,Vaqar Sharief,Lingkai Weng,Costas Agrios,Eric Shi,Brian Metcalf,Robert Newton,Steven M. Friedman,Wenqing Yao,Peggy A. Scherle,Gregory F. Hollis,Timothy Burn +33 more
TL;DR: In vitro studies demonstrate that in combination with low doses of Herceptin, selective ADAM 10 inhibitors decrease proliferation in HER2 overexpressing cell lines while inhibitors, that do not inhibit ADAM10, have no impact.
Patent
Amido compounds and their use as pharmaceuticals
TL;DR: In this article, the authors proposed a method for the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases related with aldosterone excess.